Patents Examined by Benjamin P. Blumel
  • Human antibodies to influenza hemagglutinin
    Patent number: 11453714
    Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the influenza HA for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: September 27, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lisa A. Purcell, Jonathan Viau, William Olson
  • Coated egg yolk cores, methods of making and methods of use thereof
    Patent number: 11445742
    Abstract: A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: September 20, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • Bovine respiratory disease vaccine
    Patent number: 11439701
    Abstract: The present invention relates to vaccines for treating bovine respiratory disease. Such vaccines contain a combination of bovine influenza D virus and Mannheimia haemolytica antigens. An upper respiratory infection with an IDV leads to an increased potential for M. haemolytica pathology in the lungs. The vaccines may contain further antigens from other bovine respiratory pathogens.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 13, 2022
    Assignee: Elanco US Inc
    Inventors: Lucas Huntimer, Thomas Halbur
  • Influenza peptides and compositions
    Patent number: 11439702
    Abstract: The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a T cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: September 13, 2022
    Assignee: PepTcell Limited
    Inventors: Gregory A. Stoloff, Wilson Romero Caparros-Wanderley
  • Mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof
    Patent number: 11426459
    Abstract: The disclosure relates to a mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof. In addition, the disclosure also relates to a pharmaceutical composition (e.g., a vaccine) comprising the mutant, a method for preparing the mutant, and a method of using the mutant for prevention and/or treatment of an infection of influenza virus and/or a disease (e.g., an influenza) caused by the infection.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 30, 2022
    Assignee: Xiamen University
    Inventors: Yixin Chen, Chenguang Shen, Junyu Chen, Mengya Zhang, Limin Zhang, Ningshao Xia
  • MHC class I associated peptides for prevention and treatment of zika virus
    Patent number: 11426457
    Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 30, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • Methods for preventing dengue and hepatitis A
    Patent number: 11426461
    Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: August 30, 2022
    Assignee: Takeda Vaccines, Inc.
    Inventor: Derek Wallace
  • Vaccinia viral vectors encoding chimeric virus like particles
    Patent number: 11413341
    Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: August 16, 2022
    Assignee: Geovax, Inc.
    Inventors: Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
  • Polygene influenza vaccine
    Patent number: 11389525
    Abstract: The present invention relates to a nucleic acid vaccine. Specifically, the use of a single nucleic acid sequence comprising combinations of influenza genes coding for selected hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1), matrix protein 2 (M2) and nucleoprotein (NP) interspaced with selected linkers comprising cleavage sites to produce individual proteins, together forming one polyvalent influenza vaccine for use in medicine for humans and animals.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: July 19, 2022
    Inventors: Charlotta Polacek, Anders Fomsgaard
  • Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
    Patent number: 11384339
    Abstract: The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 12, 2022
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Makoto Ozawa
  • Methods and compositions for treating cancer
    Patent number: 11382886
    Abstract: Methods for treating cancer are disclosed which comprise administering to a subject T cells which have been pretreated ex vivo or in vitro with a fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production. Still other methods comprise co-administering to a subject having a cancer characterized by a solid tumor (a) an immunotherapeutic composition targeting an antigen or ligand on the tumor cell; and (b) a compound or reagent that promotes the use of fatty acid catabolism by tumor antigen-specific T cells in the tumor microenvironment and/or T cells pretreated ex vivo with the fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production for adoptive cell transfer. Both methods may also employ co-administration of a checkpoint inhibitor.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: July 12, 2022
    Inventors: Hildegund C. J. Ertl, Ying Zhang
  • Scalable production method for AAV
    Patent number: 11377641
    Abstract: A method for producing AAV, without requiring cell lysis, is described. The method involves harvesting AAV from the supernatant. For AAV having capsids with a heparin binding site, the method involves modifying the AAV capsids and/or the culture conditions to ablate the binding between the AAV heparin binding site and the cells, thereby allowing the AAV to pass into the supernatant, i.e., media. Thus, the method of the invention provides supernatant containing high yields of AAV which have a higher degree of purity from cell membranes and intracellular materials, as compared to AAV produced using methods using a cell lysis step.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: July 5, 2022
    Inventors: Martin Lock, Luc H. Vandenberghe, James M. Wilson
  • Rabies vaccine
    Patent number: 11369694
    Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: June 28, 2022
    Assignee: CureVac AG
    Inventors: Margit Schnee, Thomas Kramps, Lothar Stitz, Benjamin Petsch
  • CHIKV RNA vaccines
    Patent number: 11364292
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: June 21, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • Simian (gorilla) adenovirus or adenoviral vectors and methods of use
    Patent number: 11359214
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 14, 2022
    Assignee: GenVec, Inc.
    Inventors: Douglas E. Brough, Jason G. D. Gall, Duncan McVey
  • Antibodies to Andes hantavirus, and methods for using same
    Patent number: 11359006
    Abstract: This invention provides isolated human antibodies and recombinant proteins comprising defined heavy chains and light chains, wherein the antibodies and recombinant proteins neutralize Andes Virus with defined IC50 values. This invention also provides related pharmaceutical compositions, treatment methods and kits.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: June 14, 2022
    Assignees: Ichor Biologies, LLC, Universidad De Concepcion
    Inventors: Maria Ines Barria, Jose Luis Garrido Ramirez, Felipe Edgardo Bravo Caceres
  • Methods for detection of flavivirus antibodies
    Patent number: 11353454
    Abstract: Isolated peptides that include one or more antigenic sites of Zika virus (ZIKV) and methods of their use and production are disclosed. The peptides can be used, for example, to detect exposure of a subject to a flavivirus infection, such as a ZIKV infection.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 7, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Surender Khurana
  • Modified immunization vectors
    Patent number: 11345928
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 31, 2022
    Assignees: Arizona Board of Regents, Conseju Superior De Investigaciones Cientificas, IPPOX Foundation
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Paramyxovirus virus-like particles as protein delivery vehicles
    Patent number: 11339375
    Abstract: Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: May 24, 2022
    Assignee: The Penn State Research Foundation
    Inventors: Anthony Paul Schmitt, Phuong Tieu Schmitt, Greeshma Vivekananda Ray
  • Methods and compounds for the treatment or prevention of severe influenza
    Patent number: 11339207
    Abstract: A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza maybe characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: May 24, 2022
    Assignee: Orph Pharma IP Company Limited
    Inventors: Paul Andrew Whittaker, Neil Edward Torbett